Differential diagnosis for PG includes atypical mycobacteria infection, clostridial infection, deep fungal infection, antiphospholipid syndrome, stasis ulcers, insect bites, Wegener’s ...

Dr. Alavi will present updated results in her presentation, which will include PG ulcer status during the observational period from the third cohort, along with other outcome measures.

InflaRx has initiated a phase 3 study of vilobelimab in patients with ulcerative pyoderma gangrenosum, the company announced in a press release. The multinational, randomized, double-blind ...

The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ulcerative pyoderma gangrenosum (PG), a rare skin disorder characterized by chronic ...

Authors of a small case series and review of superficial granulomatous PG involving the face observed that facial presentation is very rare, accounting for only 9% of 46 cases of granulomatous PG ...

The proportion of patients achieving at 100 (targeted PG ulcer healed) of the target pyoderma gangrenosum ulcer area reduction (PG Area Reduction: PGAR) at Week 26 of administration, which is the ...

About Pyoderma Gangrenosum Ulcerative PG is a rare, non-infectious, neutrophilic dermatosis recurrent skin disorder characterized by painful, necrolytic, cutaneous ulcers that can rapidly progress.